Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
Diabetologia
|
January 12, 2012
Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat
M Futamura, J Yao, X Li, et al.
Neuron
|
December 12, 2001
Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces
R Feng, C Rampon, Y P Tang, et al.
British Journal of Clinical Pharmacology
|
February 3, 2011
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males
Gary A Herman, Goutam C Mistry, Bingming Yi, et al.
British Journal of Clinical Pharmacology
|
April 19, 2013
Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects
D Hamish Wright, Julie A Stone, Tami M Crumley, et al.
Physical Review Letters
|
November 22, 2002
Observation of saturation of energy transfer between copropagating beams in a flowing plasma
R K Kirkwood, J D Moody, A B Langdon, et al.
Plos One
|
November 28, 2012
Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist
James Mu, Sajjad A Qureshi, Edward J Brady, et al.
Molecular Pharmacology
|
September 23, 2011
Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs
Jun-ichi Eiki, Yasufumi Nagata, Mayumi Futamura, et al.
Journal of Diabetes
|
June 30, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes
Adrian S Dobs, Barry J Goldstein, Pablo Aschner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
Francesco Atzori, Josep Tabernero, Andrés Cervantes, et al.
Physical Review Letters
|
September 27, 2000
Intense high-energy proton beams from Petawatt-laser irradiation of solids
R A Snavely, M H Key, S P Hatchett, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
Diabetologia
|
January 12, 2012
Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat
M Futamura, J Yao, X Li, et al.
Neuron
|
December 12, 2001
Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces
R Feng, C Rampon, Y P Tang, et al.
British Journal of Clinical Pharmacology
|
February 3, 2011
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males
Gary A Herman, Goutam C Mistry, Bingming Yi, et al.
British Journal of Clinical Pharmacology
|
April 19, 2013
Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects
D Hamish Wright, Julie A Stone, Tami M Crumley, et al.
Physical Review Letters
|
November 22, 2002
Observation of saturation of energy transfer between copropagating beams in a flowing plasma
R K Kirkwood, J D Moody, A B Langdon, et al.
Plos One
|
November 28, 2012
Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist
James Mu, Sajjad A Qureshi, Edward J Brady, et al.
Molecular Pharmacology
|
September 23, 2011
Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs
Jun-ichi Eiki, Yasufumi Nagata, Mayumi Futamura, et al.
Journal of Diabetes
|
June 30, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes
Adrian S Dobs, Barry J Goldstein, Pablo Aschner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
Francesco Atzori, Josep Tabernero, Andrés Cervantes, et al.
Physical Review Letters
|
September 27, 2000
Intense high-energy proton beams from Petawatt-laser irradiation of solids
R A Snavely, M H Key, S P Hatchett, et al.
Page
of 9